Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 11033 - 11040 of 12029 results
CMS Conducts Star Ratings Best Practices Webinar
June 26, 2013| Blog| Viewpoint
Increased Availability of Health Care Data Means More Oversight and More Litigation
June 25, 2013| Blog| Viewpoint
Contributory Infringement and Copyrights:
June 24, 2013| Blog| Viewpoint
Welcome to Privacy Monday
June 24, 2013| Blog| Viewpoint
Supreme Court Holds That Reverse Payment Patent Settlements Are Subject to Antitrust Scrutiny
June 21, 2013| Alert| Viewpoint
Court Rejects Urologists’ Appeal to Overturn Regulatory Changes to Stark Law
June 20, 2013| Blog| Viewpoint
Federal District Court Upholds Stark Regulation Ban on Physician-Owned Under Arrangement Service Providers
June 19, 2013| Advisory| Viewpoint
Texas Makes Changes to Medicaid Laws and Programs
June 19, 2013| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|